Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

More articles from Radiopharmaceutical Therapy: Radioimmunotherapy

  • You have access
    Anti-CD45 monoclonal antibody (MAb) dose optimization for astatine-211 (211At)-radioimmunotherapy (RIT) of relapsed non-Hodgkin lymphoma (NHL) in a canine model
    Sofia Frost, Brian Miller, Tom Back, Erlinda Santos, Donald Hamlin, Oliver Press, Rainer Storb, D. Scott Wilbur, Brenda Sandmaier and John Pagel
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 637;
  • You have access
    Internal radiotherapy of 188Re-IDA-D-[c(RGDfK)]2 in combination with bevacizumab or temozolomide in U87-MG tumor-bearing mice
    Byung Chul Lee, Jae Ho Jung, Byung Seok Moon and Sang Eun Kim
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 636;
  • You have access
    Anti-PSMA labeled liposomes loaded with Actinium-225 for potential antivascular alpha-radiotherapy
    Charles Zhu, Amey Bandekar, Sangeeta Ray, Martin Pomper, Frank Bruchertseifer, Alfred Morgenstern and Stavroula Sofou
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 640;
  • You have access
    Treatment of bladder cancer with Bi-213-anti-EGFR-MAb - A pilot study
    Klemens Scheidhauer, Christof Seidl, Alfred Morgenstern, Frank Bruchertseifer, Christos Apostolidis, Michael Autenrieth, Florian Kurtz, Markus Essler, Markus Schwaiger and Reingard Senekowitsch-Schmidtke
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 639;
  • You have access
    Dose escalation of first in human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab
    Ruby Meredith, Sui Shen, Patty Bunch, Michael Straughn, Julien Torgue and E. Banaga
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 638;
  • You have access
    Strong anti-tumor effect of 177Lu-tetraxetan-tetulomab in nude mice with Ramos xenografts
    Ada Repetto-Llamazares, Karianne Fleten, Sebastian Patzke, Roy Larsen and Jostein Dahle
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 635;
  • You have access
    Biodistribution and dosimetry of Lu-177 PSMA in metastasized castrate resistant prostate cancer patients
    Christiane Schuchardt, Martina Weineisen, Stefan Wiessalla, Margret Schottelius, Harshad Kulkarni, Dirk Mueller, Ingo Klette, Hans Wester and Richard Baum
    Journal of Nuclear Medicine May 1, 2014, 55 (supplement 1) 641;
  • You have access
    Enhancement of prostate-targeted radiotherapy using [131I]MIP-1095 in combination with radiosensitizing chemotherapeutic drugs
    Mathias Tesson, Robert Mairs, Kevin Maresca, John Joyal and John Babich
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 119;
  • You have access
    Monitoring Lutetium-177-anti-CAIX radioimmunotherapy with In-111-anti-CAIX SPECT in an intraperitoneal clear cell renal cell carcinoma xenograft model
    Constantijn Muselaers, Desiree Bos, Peter Mulders, Egbert Oosterwijk, Wim Oyen and Otto Boerman
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 116;
  • You have access
    Preclinical radioimmunotherapy of prostate cancer with 177Lu-11B6, a 177Lu-labeled monoclonal antibody specifically targeting free, unbound human kallikrein-related peptidase 2
    Oskar Vilhelmsson Timmermand, Thuy Tran, Erik Larsson, Kim Pettersson, Hans Lilja, David Ulmert and Sven-Erik Strand
    Journal of Nuclear Medicine May 1, 2013, 54 (supplement 2) 118;

Pages

  • Next
  • 1
  • 2
  • 3
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire